JPWO2019191728A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191728A5 JPWO2019191728A5 JP2020551572A JP2020551572A JPWO2019191728A5 JP WO2019191728 A5 JPWO2019191728 A5 JP WO2019191728A5 JP 2020551572 A JP2020551572 A JP 2020551572A JP 2020551572 A JP2020551572 A JP 2020551572A JP WO2019191728 A5 JPWO2019191728 A5 JP WO2019191728A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- pharmaceutical composition
- psma
- antibody
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 8
- 229940000425 combination drugs Drugs 0.000 claims 7
- 102100008453 FOLH1 Human genes 0.000 claims 5
- 101700036477 FOLH1 Proteins 0.000 claims 5
- 101700008337 PSMA Proteins 0.000 claims 5
- 230000003054 hormonal Effects 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 3
- 108091008116 antibody drug conjugates Proteins 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960004671 enzalutamide Drugs 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulators Drugs 0.000 claims 2
- 230000003308 immunostimulating Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 101710029981 BLLF1 Proteins 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- MFRNYXJJRJQHNW-NARUGQRUSA-N Monomethyl auristatin F Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)C([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-NARUGQRUSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 108010059074 monomethylauristatin F Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650277P | 2018-03-29 | 2018-03-29 | |
| US62/650,277 | 2018-03-29 | ||
| PCT/US2019/025057 WO2019191728A1 (en) | 2018-03-29 | 2019-03-29 | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519076A JP2021519076A (ja) | 2021-08-10 |
| JPWO2019191728A5 true JPWO2019191728A5 (es) | 2022-04-06 |
Family
ID=66103056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551572A Pending JP2021519076A (ja) | 2018-03-29 | 2019-03-29 | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210015940A1 (es) |
| EP (1) | EP3773910A1 (es) |
| JP (1) | JP2021519076A (es) |
| KR (1) | KR20200138759A (es) |
| CN (2) | CN111989138B (es) |
| AU (1) | AU2019245444A1 (es) |
| BR (1) | BR112020019611A2 (es) |
| CA (1) | CA3094985A1 (es) |
| IL (1) | IL277357A (es) |
| MX (1) | MX2020010104A (es) |
| SG (1) | SG11202009670RA (es) |
| WO (1) | WO2019191728A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021086917A1 (en) * | 2019-10-29 | 2021-05-06 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| WO2021142043A1 (en) * | 2020-01-06 | 2021-07-15 | Cytomx Therapeutics, Inc. | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof |
| WO2022081443A2 (en) * | 2020-10-12 | 2022-04-21 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| ATE66469T1 (de) | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2005074650A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
| DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
| AU2015203742B2 (en) * | 2007-06-26 | 2016-12-01 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| UA103774C2 (uk) | 2008-07-23 | 2013-11-25 | Амбркс, Інк. | Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування |
| EP3470413A3 (en) | 2011-05-27 | 2019-08-07 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| SG11201408153YA (en) * | 2012-06-07 | 2015-01-29 | Ambrx Inc | Prostate-specific membrane antigen antibody drug conjugates |
| AU2013274078A1 (en) * | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
| WO2015051199A2 (en) * | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| JP7179719B2 (ja) * | 2016-06-06 | 2022-11-29 | ポリセリックス・リミテッド | 抗体、その使用及びそのコンジュゲート |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CA3065137A1 (en) | 2017-06-02 | 2018-12-06 | Ambrx, Inc. | Methods and compositions for promoting non-natural amino acid-containing protein production |
-
2019
- 2019-03-29 US US17/042,838 patent/US20210015940A1/en active Pending
- 2019-03-29 KR KR1020207030091A patent/KR20200138759A/ko unknown
- 2019-03-29 CN CN201980025915.9A patent/CN111989138B/zh active Active
- 2019-03-29 AU AU2019245444A patent/AU2019245444A1/en active Pending
- 2019-03-29 CN CN202410093812.9A patent/CN117924503A/zh active Pending
- 2019-03-29 EP EP19717173.9A patent/EP3773910A1/en active Pending
- 2019-03-29 MX MX2020010104A patent/MX2020010104A/es unknown
- 2019-03-29 WO PCT/US2019/025057 patent/WO2019191728A1/en unknown
- 2019-03-29 BR BR112020019611-8A patent/BR112020019611A2/pt unknown
- 2019-03-29 JP JP2020551572A patent/JP2021519076A/ja active Pending
- 2019-03-29 CA CA3094985A patent/CA3094985A1/en active Pending
- 2019-03-29 SG SG11202009670RA patent/SG11202009670RA/en unknown
-
2020
- 2020-09-15 IL IL277357A patent/IL277357A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5632813B2 (ja) | リガンド免疫原複合体を用いる処置方法 | |
| US8834886B2 (en) | Camptothecin-binding moiety conjugates | |
| US8877901B2 (en) | Camptothecin-binding moiety conjugates | |
| JP4959136B2 (ja) | 細胞内で開裂可能な結合を有する免疫接合体 | |
| JP6224268B2 (ja) | 子宮内膜癌の治療において使用するためのデュオカルマイシンａｄｃ | |
| JP2008546792A5 (es) | ||
| JP2018537975A5 (es) | ||
| JP2003528924A5 (es) | ||
| JPH01246295A (ja) | 新規なリンカーを有するアントラサイクリン・イムノコンジュゲート及びその製造方法 | |
| JP2013100314A5 (es) | ||
| JP2006518737A5 (es) | ||
| JP2023530128A (ja) | 細胞結合分子とカンプトテシン類縁体との共役体 | |
| Shao | Pharmacology and therapeutic applications of enediyne antitumor antibiotics | |
| JP2003519096A5 (es) | ||
| AU619614B2 (en) | Antibody-drug conjugates | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| Fatima et al. | Benefits and challenges of antibody drug conjugates as novel form of chemotherapy | |
| PT94064B (pt) | Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem | |
| CN117924503A (zh) | 人源化抗前列腺特异性膜抗原(psma)抗体药物缀合物 | |
| JPWO2019191728A5 (es) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2021090062A5 (es) | ||
| JPS5973523A (ja) | 黄体ホルモン含有補助治療剤 | |
| CA2464947C (en) | Combination therapy for treating disease | |
| Hammam | Antibody drug conjugate, historical and future overview |